Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
P2Y12 platelet receptorSmall molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
SumecigrelPhase 3Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Est. primary completion 2026-12-30 · NCT06577519 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 June 2026Topline resultSumecigrel (formerly vicagrel)Vcare reports completed Phase III studies of Sumecigrel versus clopidogrel
China · Jiangsu Vcare PharmaTech Co., Ltd. · Source ↗
Q2 2026Filing acceptedSumecigrel (formerly vicagrel)NMPA accepts NDA for Sumecigrel Capsule (formerly vicagrel)
China, NMPA · Jiangsu Vcare PharmaTech Co., Ltd. · Source ↗

Financial reports

No financial reports recorded.